Why Should I Attend?
Japan’s pharma industry is the 2nd largest in Asia and the third-largest worldwide following the US and China. Gathering over 550 exhibitors and 20,000 pharma professionals from around the world, CPhI Japan is the ideal platform to meet the biggest pharma companies to tap into this attractive market and source the latest technologies and innovative products!
Network
Network with peers online and in-person to connect with potential business prospects and collaborate, reach goals and overcome challenges.
Learn
With our jam-packed conference schedule, you’ll learn from experts, leaders, and fresh new voices, so you can stay ahead of pharma trends in Japan.
Source
Source products and services from Japan’s most inventive pharma solution providers, helping you forge new partnerships and take your business to the next level.
Innovate
Innovate with
thousands of your peers, take inspiration from visionary keynotes, and stay up to date with trending content from every aspect of the pharma supply chain.
Who is it for?
CPHI Japan is for any pharma professional looking to connect to the right people and products in the Asian region, to help find high quality, low costs pharma solutions, transform their business and improve their bottom line.
Here’s a quick overview of who attends CPHI Japan...
79
countries represented
61%
have purchasing responsibility
48%
are C-Suite Executives
Why Japanese Pharmaceutical Industry?
- Japan is the 2nd largest Pharma market in the Asia-Pacific region
- Per capita pharmaceutical spending among world’s highest.
- Very strong patented drugs market due to the country’s wealth and preference for branded drugs
- High demand for pharmaceuticals driven by an ageing population
- Well-developed healthcare system with high government contribution to overall costs
The opportunity
- The underdeveloped generic drug sector is set to play greater role in Japanese pharma market. Due to government promotion of sector, the need for replenishment of a recent drug shortage, as well as the expiry of a number of blockbuster drug patents.
- Increased cooperation between domestic and foreign manufactures, both at home and aboard, is likely to boost sales and growth marketing presence.
- An ageing population and rising number of chronic and long-term diseases require more innovative products.
- The Sakigake designation for innovative medicines will provide an accelerated approval process, encouraging the introduction of more high-value medicines
It was extremely pleasant and refreshing to reconnect in person with vendors and industry professionals. I had very productive meetings, and I accomplished more than expected.
CPhI Japan is organised in accordance with Informa’s AllSecure health and safety standard. As the world’s leading events’ organiser, Informa has developed a detailed set of enhanced measures to provide the highest levels of hygiene and safety at its events, providing everyone with reassurance and confidence they are participating in a safe and controlled environment.
